Page last updated: 2024-12-08
nordamnacanthal
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
nordamnacanthal: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 160712 |
| CHEMBL ID | 2297225 |
| SCHEMBL ID | 16227182 |
| MeSH ID | M0439061 |
Synonyms (9)
| Synonym |
|---|
| 2-anthracenecarboxaldehyde, 9,10-dihydro-1,3-dihydroxy-9,10-dioxo- |
| nordamnacanthal |
| 3736-59-2 |
| 1,3-dihydroxy-9,10-dioxo-anthracene-2-carbaldehyde |
| ccris 6442 |
| CHEMBL2297225 |
| SCHEMBL16227182 |
| DTXSID10190805 |
| 1,3-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carbaldehyde |
Research Excerpts
Actions
| Excerpt | Reference | Relevance |
|---|---|---|
| "Nordamnacanthal managed to inhibit the growth and induce cell death in MDA-MB231 and MCF-7 cell lines in vitro and cease the tumor progression of 4T1 cells in vivo. " | ( Subchronic toxicity, immunoregulation and anti-breast tumor effect of Nordamnacantal, an anthraquinone extracted from the stems of Morinda citrifolia L. Abu, N; Alitheen, NB; Ismail, NH; Mohamad, NE; Nordin, N; Rasol, NE; Romli, MF; Subramani, T; Yeap, SK; Zamberi, NR, 2018) | 1.92 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with nordamnacanthal was also able to increase tumor immunity as evidenced by the immunophenotyping of the spleen and YAC-1 cytotoxicity assays." | ( Subchronic toxicity, immunoregulation and anti-breast tumor effect of Nordamnacantal, an anthraquinone extracted from the stems of Morinda citrifolia L. Abu, N; Alitheen, NB; Ismail, NH; Mohamad, NE; Nordin, N; Rasol, NE; Romli, MF; Subramani, T; Yeap, SK; Zamberi, NR, 2018) | 0.82 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.17
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.17) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||